Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 4
2007 2
2008 2
2009 2
2010 2
2011 6
2013 6
2014 3
2015 5
2016 1
2017 2
2018 1
2019 1
2020 3
2021 2
2022 2
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II.
Muenzer J, Burton BK, Harmatz P, Gutiérrez-Solana LG, Ruiz-Garcia M, Jones SA, Guffon N, Inbar-Feigenberg M, Bratkovic D, Hale M, Wu Y, Yee KS, Whiteman DAH, Alexanderian D; SHP609-302 study group. Muenzer J, et al. Mol Genet Metab. 2022 Sep-Oct;137(1-2):92-103. doi: 10.1016/j.ymgme.2022.07.016. Epub 2022 Aug 2. Mol Genet Metab. 2022. PMID: 35961250 Free article. Clinical Trial.
A formulation of idursulfase for intrathecal administration (idursulfase-IT) is under investigation for the treatment of neuronopathic MPS II. ...Overall, 25.0% of patients had at least one adverse event (AE) related to idursulfase-IT; most trea …
A formulation of idursulfase for intrathecal administration (idursulfase-IT) is under investigation for the treatment of neuro …
Idursulfase: I2S, iduronato-2-sulfatase.
[No authors listed] [No authors listed] Drugs R D. 2006;7(4):254-8. doi: 10.2165/00126839-200607040-00005. Drugs R D. 2006. PMID: 16784250 Review. No abstract available.
IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.
Kim J, Park MR, Kim DS, Lee JO, Maeng SH, Cho SY, Han Y, Ahn K, Jin DK. Kim J, et al. Allergy. 2013 Jun;68(6):796-802. doi: 10.1111/all.12155. Epub 2013 Apr 29. Allergy. 2013. PMID: 23621439
However, various adverse events can occur by the infusion of idursulfase. The purpose was to evaluate the occurrence of infusion-related allergic reactions, including anaphylaxis, to idursulfase in patients with MPS II receiving ERT and to elucidate its possi …
However, various adverse events can occur by the infusion of idursulfase. The purpose was to evaluate the occurrence of infusi …
A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II.
Muenzer J, Hendriksz CJ, Fan Z, Vijayaraghavan S, Perry V, Santra S, Solanki GA, Mascelli MA, Pan L, Wang N, Sciarappa K, Barbier AJ. Muenzer J, et al. Genet Med. 2016 Jan;18(1):73-81. doi: 10.1038/gim.2015.36. Epub 2015 Apr 2. Genet Med. 2016. PMID: 25834948 Free article. Clinical Trial.
We examined the safety of idursulfase formulated for intrathecal administration (idursulfase-IT) via intrathecal drug delivery device (IDDD). ...RESULTS: No serious adverse events related to idursulfase-IT were observed. Surgical revision/removal of th …
We examined the safety of idursulfase formulated for intrathecal administration (idursulfase-IT) via intrathecal drug delivery …
Idursulfase in Hunter syndrome treatment.
Zareba G. Zareba G. Drugs Today (Barc). 2007 Nov;43(11):759-67. doi: 10.1358/dot.2007.43.11.1157619. Drugs Today (Barc). 2007. PMID: 18174963 Review.
Results of the randomized, double-blind, placebo-controlled phase II/III clinical trial of idursulfase demonstrated that weekly infusions of idursulfase increase walking distance and improve pulmonary function as well as reduce organ size and urinary glycosaminoglyc …
Results of the randomized, double-blind, placebo-controlled phase II/III clinical trial of idursulfase demonstrated that weekly infus …
Safety evaluation of chronic intrathecal administration of idursulfase-IT in cynomolgus monkeys.
Felice BR, Wright TL, Boyd RB, Butt MT, Pfeifer RW, Pan J, Ruiz JA, Heartlein MW, Calias P. Felice BR, et al. Toxicol Pathol. 2011 Aug;39(5):879-92. doi: 10.1177/0192623311409595. Epub 2011 May 31. Toxicol Pathol. 2011. PMID: 21628718
In this chronic safety study, cynomolgus monkeys were dosed weekly with IV idursulfase (0.5 mg/kg) and every four weeks with idursulfase-IT (3, 30, and 100 mg) for six months, with device and vehicle controls treated similarly (n = 6, all groups). ...The no-observed …
In this chronic safety study, cynomolgus monkeys were dosed weekly with IV idursulfase (0.5 mg/kg) and every four weeks with idurs …
A review of the clinical outcomes in idursulfase-treated and untreated Filipino patients with mucopolysaccharidosis type II: data from the local lysosomal storage disease registry.
Racoma MJC, Calibag MKKB, Cordero CP, Abacan MAR, Chiong MAD. Racoma MJC, et al. Orphanet J Rare Dis. 2021 Jul 21;16(1):323. doi: 10.1186/s13023-021-01875-5. Orphanet J Rare Dis. 2021. PMID: 34289859 Free PMC article. Review.
METHODS: A retrospective audit of records of MPS II patients listed in the registry was done. Qualified patients were divided into two cohorts: idursulfase-treated group (patients on enzyme replacement therapy, ERT, for 6 months) and untreated group. ...Improvements in the …
METHODS: A retrospective audit of records of MPS II patients listed in the registry was done. Qualified patients were divided into two cohor …
Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS).
Burton BK, Whiteman DA; HOS Investigators. Burton BK, et al. Mol Genet Metab. 2011 Jun;103(2):113-20. doi: 10.1016/j.ymgme.2011.02.018. Epub 2011 Mar 4. Mol Genet Metab. 2011. PMID: 21439875
STUDY DESIGN: Information in HOS regarding the frequency, timing and severity of reported IRRs during the first year of treatment with idursulfase was analyzed, and formation of antibodies to idursulfase was characterized. ...No patient in this analysis discontinued …
STUDY DESIGN: Information in HOS regarding the frequency, timing and severity of reported IRRs during the first year of treatment with id …
Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome).
Pano A, Barbier AJ, Bielefeld B, Whiteman DA, Amato DA. Pano A, et al. Orphanet J Rare Dis. 2015 Apr 24;10:50. doi: 10.1186/s13023-015-0265-2. Orphanet J Rare Dis. 2015. PMID: 25902842 Free PMC article. Clinical Trial.
BACKGROUND: Twenty-eight treatment-naive mucopolysaccharidosis II patients (16 months-7.5 years) received 0.5 mg/kg idursulfase weekly for one year in NCT00607386. Serum anti-idursulfase immunoglobulin G antibodies (Abs) were seen in 68% of patients. ...Liver size a …
BACKGROUND: Twenty-eight treatment-naive mucopolysaccharidosis II patients (16 months-7.5 years) received 0.5 mg/kg idursulfase weekl …
39 results